Aprea logo 445pt.png
Aprea Therapeutics Announces Results of Primary Endpoint from Phase 3 Trial of Eprenetapopt in TP53 Mutant Myelodysplastic Syndromes (MDS)
December 28, 2020 08:00 ET | Aprea Therapeutics
The trial failed to meet its primary endpoint of complete remission (CR) rateCR rate was 53% higher in eprenetapopt with AZA arm compared to AZA alone, but did not reach statistical significance ...
Geron-logo-black-xsmall.png
Geron Corporation Reports Third Quarter 2020 Financial Results and Current Events
November 05, 2020 16:05 ET | Geron Corporation
FOSTER CITY, Calif., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today reported financial results for the third quarter ended...
Onconova New Letterhead Logo (002).JPG
Onconova Therapeutics Highlights Corporate Progress and Reports Second Quarter 2020 Financial Results
August 12, 2020 16:05 ET | Onconova Therapeutics, Inc.
INSPIRE Phase 3 trial survival events reachedTopline data anticipated Q3-2020 Conference call and webcast scheduled today, August 12, at 4:30 p.m. ET NEWTOWN, Pa., Aug. 12, 2020 (GLOBE NEWSWIRE)...
Aprea logo 445pt.png
Aprea Therapeutics Reports Second Quarter 2020 Financial Results and Provides Update on Business Operations
August 11, 2020 16:15 ET | Aprea Therapeutics
BOSTON, Aug. 11, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate...
Onconova New Letterhead Logo (002).JPG
Onconova Therapeutics to Provide Corporate Update and Second Quarter 2020 Earnings on August 12, 2020
August 07, 2020 08:00 ET | Onconova Therapeutics, Inc.
NEWTOWN, Pa., Aug. 07, 2020 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel products to treat...
Onconova New Letterhead Logo (002).JPG
Onconova Therapeutics Announces that the Required Number of Survival Events Has Been Reached for the Pivotal Phase 3 INSPIRE Trial Data Analysis
July 29, 2020 13:30 ET | Onconova Therapeutics, Inc.
NEWTOWN, Pa., July 29, 2020 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel products to treat...
Onconova New Letterhead Logo (002).JPG
Onconova Therapeutics Announces Publication of Preclinical Data Supporting Rigosertib’s Mechanism of Action as a Targeted Anticancer Therapy
July 23, 2020 08:00 ET | Onconova Therapeutics, Inc.
NEWTOWN, Pa., July 23, 2020 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat...
Onconova New Letterhead Logo (002).JPG
Onconova Therapeutics Announces Publication of Phase 1 Results in Leukemia Research Exploring Oral Rigosertib in Combination with Azacitidine in Higher-Risk MDS
July 07, 2020 08:00 ET | Onconova Therapeutics, Inc.
RAS-focused mechanism of action and manageable side effect profile indicate potential promise for oral rigosertib as part of future combination therapies NEWTOWN, Pa., July 07, 2020 (GLOBE...
Geron-logo-black-xsmall.png
Geron Receives Positive Opinion from the EMA Committee for Orphan Medicinal Products for Orphan Drug Designation in the European Union for Imetelstat to Treat Myelodysplastic Syndromes
July 01, 2020 08:30 ET | Geron Corporation
Designation would provide 10-year period of marketing exclusivity in the European Union after product approvalPatients are currently enrolling in a Geron-sponsored Phase 3 clinical trial in lower risk...
Onconova New Letterhead Logo (002).JPG
Onconova Therapeutics Announces Participation in Noble Capital Markets Investor Webinar
June 23, 2020 08:00 ET | Onconova Therapeutics, Inc.
NEWTOWN, Pa., June 23, 2020 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel products to treat...